Background
==========

Breast cancer (BC) is the most frequently diagnosed cancer and ranks the sixth leading cause of cancer-related death in Chinese women \[[@b1-medscimonit-24-5988]\]. Weight gain and obesity are common occurrences in women receiving adjuvant chemotherapy for BC, with the 50--96% prevalence commonly reported \[[@b2-medscimonit-24-5988]--[@b4-medscimonit-24-5988]\]. Many studies have indicated that weight gain during chemotherapy not only adversely affect patients' cardiovascular health and life quality \[[@b5-medscimonit-24-5988],[@b6-medscimonit-24-5988]\], but also increases the risk of BC recurrence and death \[[@b7-medscimonit-24-5988],[@b8-medscimonit-24-5988]\]. Multiple reasons for weight gain have also been suggested, including premenopausal status, high-calorie diet, decreased physical activity, and multi-agent chemotherapy regimen, although the underlying mechanism has not been clearly elucidated \[[@b3-medscimonit-24-5988],[@b9-medscimonit-24-5988]--[@b11-medscimonit-24-5988]\].

Studies indicated that weight gain during chemotherapy was associated with an increase in fat mass and decrease in lean body mass \[[@b12-medscimonit-24-5988]\]. However, most previous researches focused on changes in body weight or body mass index (BMI) \[[@b2-medscimonit-24-5988],[@b13-medscimonit-24-5988],[@b14-medscimonit-24-5988]\], which might not accurately depict changes in adipose or lean tissue \[[@b15-medscimonit-24-5988]\]. It is increasingly recognized that percent body fat (%BF), which can accurately measure the amount of whole body fat mass, is a better and more practical measure of obesity, especially for Asian populations \[[@b16-medscimonit-24-5988],[@b17-medscimonit-24-5988]\]. As a result, a study of change in %BF during BC chemotherapy might not only provide important information about the mechanism by which weight gain influences prognosis, but might also contribute to development of a better weight management program.

The objective of this study was to investigate %BF change and identify the associated risk factors among Chinese women receiving chemotherapy for BC. Our initial hypothesis was that women were more likely to experience changes in %BF than body weight during BC chemotherapy.

Material and Methods
====================

Study population
----------------

This was a prospective longitudinal study carried out in Comprehensive Breast Health Center, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine from June 2016 to October 2017. Patients who met the following criteria were enrolled in the study: 1) histologically diagnosed with stage I--III invasive BC and had received radical surgery; 2) within 1 month of starting adjuvant chemotherapy; 3) adult Chinese women (≥18 years of age), able to speak and read Chinese. Patients would be excluded from the study if they had health conditions that contraindicated exercise participation, previous treatment for another cancer, or mental illness that prevented survey comprehension. This study was conducted according to the principles of Declaration of Helsinki and was approved by the Ethics Committees of our hospital (R-2016-39). All participants provided written informed consent.

Data collection
---------------

Demographic and clinical data were recorded by interviews and reviews of patients' medical records, including age, menopausal status, tumor stage, histological type, presence of receptors \[estrogen receptor, progesterone receptor, and human epidermal growth factor 2 (HER2) receptor\], chemotherapy regimens, daily caloric intake, and physical activity during chemotherapy sessions. Of these, menopausal status was established when at least 12 months elapsed from the last menstrual period. Tumor was staged according to the American Joint Committee on Cancer (AJCC) TNM classification (Version 7.0). According to tumor receptor characteristics (BC molecular type), patients were classified as luminal A/B (positive estrogen and/or progesterone receptors), HER2 (HER2 positive, positive and negative hormone receptors) or basal type (triple-negative BC). Chemotherapy regimens were divided into 4 groups: carboplatin-, anthracycline-, taxane-, or anthracycline plus taxane-based chemotherapy.

At the end of chemotherapy, each participant completed a food frequency questionnaire (FFQ) \[[@b18-medscimonit-24-5988]\] and an International Physical Activity Questionnaire (IPAQ) \[[@b19-medscimonit-24-5988]\] to assess the daily caloric intake and moderate physical activity level over the previous 3 months, respectively. A total of 100 food items and food groups were included in the FFQ and that covers about 90% of commonly consumed foods in Shanghai. The quantity, frequency of consumption (daily, weekly, monthly, or never) for each item or food group was recorded with the aid of photographs to illustrate portion sizes. Dietary intake data were converted into nutrient intake data using the continuously updated in-house nutrient database based on the nutritional software of traditional Chinese medicine combining with western medicine (NCCW) (Version 11.0, Qingdao University Medical College, China), which reflected the China Food Composition. The American Cancer Society recommends 30 minutes or more of moderate physical activity at least 5 days per week for BC patients, so this study focused on the level of moderate physical activity. According to IPAQ guidelines, moderate physical activity was defined as activities causing little to moderate rise in breathing and heart rate \[3.0--6.0 metabolic equivalents (METs)\]. The physical activity energy expenditure was calculated by multiplying weekly frequency, usual duration, and metabolic equivalent of the respective activity category (METs-minutes/week) \[[@b19-medscimonit-24-5988]\].

A series of anthropometric parameters were also collected by the study's registered nurse on the first day before and after chemotherapy, including weight, height, waist circumference (WC), hip circumference, and %BF. All the tests were performed in the morning. Participants were asked to fast overnight, to avoid any vigorous physical activity for at least 48 hours before the procedure, and to urinate or defecate before the measurements were taken. For all participants, weight was measured to the nearest 0.1 kg and height to the nearest 0.5 cm, without shoes and in light clothing. WC was measured in cm at the level of the umbilicus with the participant standing. Hip circumference was measured in cm at the greatest protrusion of the buttocks. BMI and waist-to-hip ratio (WHR) were calculated as weight/height^2^ (kg/m^2^) and waist/hip (both in cm), respectively. %BF was measured by bioelectrical impedance assessment (BIA) device (InBody 770, Biospace, Korea), in accordance with the manufacturer's guidelines. Patients were allowed to rest in the supine position for 10 minutes before performing this test.

Statistical analysis
--------------------

Statistical analyses were performed with SPSS software (Version 19.0, IBM, Chicago, IL, USA). Chi-square and Student's *t*-test were utilized to analyze the differences in patient characteristics and outcomes. To identify the risk factors for %BF change, multiple logistic regression analysis was conducted. The odds ratio (OR) and 95% confidence interval (95% CI) were estimated for each factor. For all tests, a *P* value of \<0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

There were 140 BC patients included in this study, and the general characteristics of the study population are summarized in [Table 1](#t1-medscimonit-24-5988){ref-type="table"}. Among them, 56 women were premenopausal and 84 were postmenopausal, with a median age of 53 years (range, 20--81 years). Fifty patients were diagnosed with stage I BC, 74 patients had stage II BC, and 16 patients had stage III BC. According to tumor receptor characteristics, 73 cases were classified as luminal A/B, 40 cases as HER2 and 27 cases as basal type. All the patients received 4--8 cycles of adjuvant chemotherapy, with a median duration of 18 weeks (range, 12--24 weeks). The chemotherapy regimens included carboplatin- (n=14), anthracycline- (n=14), taxane- (n=48), and anthracycline plus taxane-based (n=64). During chemotherapy sessions, the median daily caloric intake and moderate physical activity level of the total cohort were 1554 calories and 310 METs-minutes/week, respectively.

Changes in anthropometric characteristics
-----------------------------------------

A series of anthropometric parameters were measured before and after chemotherapy, and a significant gain was observed in weight (*P*\<0.001), BMI (*P*=0.006), and %BF (*P*\<0.001) ([Table 2](#t2-medscimonit-24-5988){ref-type="table"}). The mean weight and %BF changes for all participations were 1.4±2.3 kg and 0.9±2.5%, respectively, with 74 patients gaining weight (mean weight gain=2.1±1.9 kg) and 82 gaining %BF (mean %BF gain=1.3±2.2%). Among the patients with %BF gain, 24 gained less than 2.5% of the baseline %BF, 36 gained between 2.5% and 5.0%, and 22 gained more than 5%. We also observed that 61 patients and 55 patients experienced a loss in body weight (0.7±1.6 kg) and %BF (0.4%±2.0%), respectively. We further examined the %BF change stratified by menopausal status and found that both groups showed a significant %BF gain after chemotherapy (*P*\<0.001 and *P*=0.004, respectively). Notably, premenopausal women had a greater mean %BF gain than postmenopausal women (1.1±2.0% *vs.* 0.8±2.2%, *P*=0.018) ([Table 3](#t3-medscimonit-24-5988){ref-type="table"}).

Risk factors associated with %BF gain
-------------------------------------

Multivariate logistic analysis was performed to identify risk factors associated with %BF gain of more than 2.5% of the baseline value after chemotherapy ([Table 4](#t4-medscimonit-24-5988){ref-type="table"}). The results indicated that age \<50 years (OR=1.27, 95% CI: 1.11--2.34), anthracycline plus taxane-based chemotherapy (OR=1.18, 95% CI: 1.07--1.94), daily caloric intake ≥1600 calories (OR=1.46, 95% CI: 1.20--3.03) and physical activity ≤450 METs-minutes/week (OR=1.37, 95% CI: 1.13--2.68) were independent variables that inducted %BF gain. In addition, compared with postmenopausal women, premenopausal women showed a 1.33-fold (95% CI: 1.10--2.62) increased risk to develop %BF gain during chemotherapy sessions. No significant association was detected for other variables, including baseline weight, tumor stage, histological type, molecular type, chemotherapy length, etc.

Discussion
==========

Weight gain is a common side effect observed in female patients undergoing chemotherapy for BC \[[@b2-medscimonit-24-5988],[@b3-medscimonit-24-5988]\]. Evidence exists that obesity not only significantly increases the risk of developing BC, but also is a major risk factor for recurrent disease and decreased survival \[[@b7-medscimonit-24-5988],[@b8-medscimonit-24-5988],[@b20-medscimonit-24-5988]\]. Camoriano et al. \[[@b21-medscimonit-24-5988]\] reported that premenopausal patients who gained over 5.9 kg had a risk of relapse 1.5 times greater and a risk of death 1.6 times greater than women gaining less weight. Several mechanisms have been proposed to explain the adverse effect of obesity and weight gain on BC prognosis. The major mechanism is the elevated estrogen synthesis by adipose tissue which stimulated tumor growth and metastasis, especially in postmenopausal women \[[@b22-medscimonit-24-5988],[@b23-medscimonit-24-5988]\]. Insulin and some adipokines also may influence BC progression and outcome by enhancing angiogenesis \[[@b24-medscimonit-24-5988]\]. Hence, it is important to recognize that weight management is indispensable for improving BC patients' long-term health.

Body weight and BMI are the most commonly used measures of overweight and obesity. However, recent studies have demonstrated that %BF is a more important predictor of weight management decision-making than body weight or BMI, particularly in Chinese female population \[[@b25-medscimonit-24-5988],[@b26-medscimonit-24-5988]\]. Freedman et al. \[[@b27-medscimonit-24-5988]\] suggested some women with BC might not experience significant changes in weight or BMI after chemotherapy, but they appeared to undergo unfavorable changes in body composition. A comparable result was observed in our study, where 52.9% and 58.6% of the 140 female BC patients experienced gains in weight and %BF after chemotherapy, respectively, with mean increases of 2.1 kg and 1.3%, respectively. Moreover, 58 patients gained %BF over 2.5% of the baseline value. This suggested that women were more likely to experience changes in body composition than body weight during chemotherapy for BC. In addition, our study found that premenopausal women exhibited a greater %BF gain than postmenopausal women during chemotherapy (*P*=0.018), as has been indicated by a number of investigators \[[@b27-medscimonit-24-5988],[@b28-medscimonit-24-5988]\]. From the aforementioned results, we conclude that patients should pay more attention to the management of %BF rather than body weight during BC treatment.

WC and WHR are also widely used to evaluate obesity. Compared with BMI, they can better reflect the accumulation of intra-abdominal fat \[[@b26-medscimonit-24-5988]\]. Recent studies have revealed that the circulating sex hormone concentrations could influence body fat content and distribution \[[@b23-medscimonit-24-5988]\]. Instead, different adipose tissue distribution may reflect an altered hormonal profile of BC patients and thus possibly affect prognosis and response to therapy \[[@b29-medscimonit-24-5988],[@b30-medscimonit-24-5988]\]. Studies have also showed that WC and WHR are positively correlated with the risk and prognosis of BC \[[@b31-medscimonit-24-5988]--[@b33-medscimonit-24-5988]\]. A study by Harvie found that WC increased during chemotherapy and continued to increase in the post-chemotherapy period so that at 1 year, BC patients had increased 5.1 cm from baseline \[[@b34-medscimonit-24-5988]\]. In our study, there appeared to be an increase in WC and WHR after chemotherapy, but these changes were not statistically significant. As our median observation time was only 18 weeks, an extension of follow-up would help draw definitive conclusion. This is an issue which we intend to address in further work.

In the present study, we also evaluated the potential risk factors for %BF gain after BC chemotherapy. The results showed that, compared with postmenopausal women, premenopausal women displayed significantly higher risk for %BF gain. This was consistent with the finding from other studies \[[@b28-medscimonit-24-5988]\]. Research suggested that premature amenorrhea caused by adjuvant chemotherapy might trigger increased fat accumulation and alterations in fat distribution \[[@b21-medscimonit-24-5988]\]. We also found that the younger group of women were more likely to have %BF gain than the older group, and this might be because the cutoff age of 50 years in this study was close to the average age of menopause in our local population. In addition, our study showed that the risk of %BF gain appeared to be greater in women receiving multi-agent than single agent chemotherapy regime. A similar finding was reported by Demark-Wahnefried et al. \[[@b11-medscimonit-24-5988]\] and Jatoi et al. \[[@b35-medscimonit-24-5988]\]. But the reason for this phenomenon has not been thoroughly clarified. Furthermore, a variety of studies have highlighted that lifestyle has an important impact on body composition changes \[[@b9-medscimonit-24-5988],[@b10-medscimonit-24-5988],[@b36-medscimonit-24-5988]\]. It was obvious in this study that increased dietary intake and reduced energy expenditure were found to contribute significantly to %BF gain during BC chemotherapy. In addition to these factors, baseline weight, tumor stage, and treatment length have also been reported to be associated with %BF gain \[[@b22-medscimonit-24-5988],[@b37-medscimonit-24-5988],[@b38-medscimonit-24-5988]\], but no significant association was detected in our study. The explanations for these differences remain to be elucidated and might well give insights into the mechanisms involved.

To our knowledge, this is the first study specifically designed to investigate %BF change in Chinese women after adjuvant chemotherapy for BC, but some limitations should also be noted. First, the sample size of this study was relatively small, which might place a limitation on the assessment of creativity. Second, bioelectrical impedance-derived body composition might be affected by hydration status, ambient temperature, and recent exercise. Last but not least, other risk factors not included in this study cannot be examined for confounding effects. Hence, further validation of our findings is warranted.

Conclusions
===========

Our study results suggested that %BF gain occurred frequently in Chinese women after adjuvant chemotherapy for BC, especially in premenopausal women. Moreover, premenopausal status, younger age, multi-agent chemotherapy regimen, high-calorie diet, and decreased physical activity were the potential risk factors for %BF gain. %BF management should be an integral part of the entire course of BC treatment, and our findings provide valuable information for the development of interventions to curb deleterious changes in %BF.
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###### 

General characteristics of study population.

  Variable                                        Total (n=140)
  ----------------------------------------------- -------------------
  Age, years                                      53 (20--81)
  Menopausal status                               
   Premenopausal                                  56 (40.0%)
   Postmenopausal                                 84 (60.0%)
  Tumor stage                                     
   I                                              50 (35.7%)
   II                                             74 (52.9%)
   III                                            16 (11.4%)
  Histological type                               
   Infiltrating ductal carcinoma                  105 (75.0%)
   Ductal carcinoma *in situ*                     25 (17.8%)
   Infiltrating lobular carcinoma                 2 (1.4%)
   Colloid carcinoma                              4 (2.9%)
   Other types                                    4 (2.9%)
  Molecular type                                  
   Luminal A/B                                    73 (52.1%)
   HER2                                           40 (28.6%)
   Basal                                          27 (19.3%)
  Chemotherapy regimen                            
   Carboplatin-based                              14 (10.0%)
   Anthracycline-based                            14 (10.0%)
   Taxane-based                                   48 (34.3%)
   Anthracycline plus taxane-based                64 (45.7%)
  Chemotherapy length, weeks                      18 (12--24)
  Daily caloric intake, cals                      1554 (1012--2307)
  Moderate physical activity, METs-minutes/week   310 (0--1260)

HER2 -- human epidermal growth factor 2; MET -- metabolic equivalents of the task.

###### 

Changes in anthropometric characteristics after chemotherapy.

  Variable       Before chemotherapy   After chemotherapy   *P* value
  -------------- --------------------- -------------------- -------------
  Weight, kg     59.7±8.1              61.1±8.5             **\<0.001**
  BMI, kg/m^2^   23.4±3.2              23.7±3.4             **0.006**
  WC, cm         84.0±3.6              84.0±4.6             0.694
  WHR            0.90±0.05             0.90±0.09            0.371
  %BF            32.9±5.9%             33.8±6.7%            **\<0.001**

BMI -- body mass index; WC -- waist circumference; WHR -- waist-to-hip ratio; %BF -- percent body fat.

###### 

Changes in %BF after chemotherapy.

  Variable                  Total (n=140)   Premenopausal (n=56)   Postmenopausal (n=84)
  ------------------------- --------------- ---------------------- -----------------------
  Same %BF                  3 (2.1%)        1 (1.8%)               2 (2.4%)
  %BF loss                  55 (39.3%)      12 (21.4%)             43 (51.2%)
  %BF gain                  82 (58.6%)      43 (76.8%)             39 (46.4%)
   \<2.5%                   24              12                     12
   2.5--5%                  36              19                     17
   \>5%                     22              12                     10
  %BF before chemotherapy   /               31.4±4.9%              33.8±6.4%
  %BF after chemotherapy    /               32.5±6.2%              34.6±7.9%
  P value, intra-group      /               **\<0.001**            **0.004**

%BF -- percent body fat.

###### 

Multivariate logistic analysis of risk factors associated with %BF gain.

  Variable                                        %BF gain ≥2.5% (n=58)   Other %BF change (n=82)   Multivariate        
  ----------------------------------------------- ----------------------- ------------------------- ------------------- -------
  Age, years                                                                                                            
   ≥50                                            26                      54                        1 (reference)       
   \<50                                           32                      28                        1.27 (1.11--2.34)   0.019
  Menopausal status                                                                                                     
   Postmenopausal                                 27                      57                        1 (reference)       
   Premenopausal                                  31                      25                        1.33 (1.10--2.62)   0.021
  Baseline weight, kg                                                                                                   
   \<60                                           32                      47                        1 (reference)       
   ≥60                                            26                      35                        1.09 (0.48--1.92)   0.074
  Baseline BMI, kg/m^2^                                                                                                 
   \<24                                           27                      51                        1 (reference)       
   ≥24                                            31                      31                        0.96 (0.34--1.65)   0.350
  Baseline WC, cm                                                                                                       
   \<85                                           30                      45                        1 (reference)       
   ≥85                                            28                      37                        1.13 (0.36--1.83)   0.692
  Baseline WHR                                                                                                          
   \<0.85                                         28                      48                        1 (reference)       
   ≥0.85                                          30                      34                        1.20 (0.28--2.01)   0.471
  Baseline %BF                                                                                                          
   \<30.0%                                        25                      38                        1 (reference)       
   ≥30.0%                                         33                      44                        1.17 (0.53--2.78)   0.518
  Tumor stage                                                                                                           
   I                                              21                      29                        1 (reference)       
   II--III                                        37                      53                        0.92 (0.42--1.76)   0.273
  Histological type                                                                                                     
   Infiltrating ductal carcinoma                  40                      65                        1 (reference)       
   Others                                         18                      17                        1.90 (0.75--4.79)   0.174
  Molecular type                                                                                                        
   Luminal A/B                                                                                                          
   Present                                        32                      41                        1 (reference)       
   Absent                                         26                      41                        0.73 (0.14--3.17)   0.205
  HER2                                                                                                                  
   Present                                        20                      20                        1 (reference)       
   Absent                                         38                      62                        1.04 (0.53--3.80)   0.142
  Basal                                                                                                                 
   Present                                        10                      17                        1 (reference)       
   Absent                                         48                      65                        1.98 (0.29--5.51)   0.493
  Chemotherapy regimen                                                                                                  
   Others                                         25                      51                        1 (reference)       
   Anthracycline plus taxane-based                33                      31                        1.18 (1.07--1.94)   0.043
  Chemotherapy length, weeks                                                                                            
   \<18                                           21                      34                        1 (reference)       
   ≥18                                            37                      48                        0.80 (0.20--2.89)   0.762
  Daily caloric intake, cals                                                                                            
   \<1600                                         19                      47                        1 (reference)       
   ≥1600                                          39                      35                        1.46 (1.20--3.03)   0.012
  Moderate physical activity, METs-minutes/week                                                                         
   \>450                                          14                      40                        1 (reference)       
   ≤450                                           44                      42                        1.37 (1.13--2.68)   0.010

%BF -- percent body fat; OR -- odds ratio; CI -- confidence interval; BMI -- body mass index; WC -- waist circumference; WHR -- waist-to-hip ratio; HER2 -- human epidermal growth factor 2; MET -- metabolic equivalents of the task.
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